Recent advances in the development of cinnamic-like derivatives as antituberculosis agents

Expert Opinion on Therapeutic Patents

Volumn 22, Issue 2, 2012, Pages 155-168

  De, Prithwiraj ^a,b   De, Kavita ^a,b   Veau, Damien ^a,b   Bedos Belval, Florence ^a,b,c   Chassaing, Stefan ^a,b,c   Baltas, Michel ^a,b  

^a UNIVERSITÉ PAUL SABATIER   (France)

^b CNRS   (France)

^c Université Paul Sabatier Toulouse III   (France)

Author keywords

Anti TB activity; Arylpropenoid compounds; Chalcone; Cinnamic acid; Natural products; Tuberculosis

Indexed keywords

2 [4 (1H INDOL 3 YL)PIPERIDIN 1 YLAMINO] 2 [1 [3 (3,4,5 TRIFLUORO PHENYL)ACRYLOYL]PIPERIDIN 4 YL]ACETIC ACID; 2 HYDROXY 4',6 DIMETHOXY CHALCONE; 2 HYDROXY 4,4' DIMETHOXY CHALCONE; 2,3' DIHYDROXYCHALCONE; 3 (BENZO[D][1,3]DIOXOL 5 YL) 1 (3 HYDROXYPHENYL)PROP 2 EN 1 ONE; 3' AMINO 2 HYDROXYCHALCONE; 3,4,5 TRIFLUOROCINNAMYLAMIDE; 4 ALKOXYCINNAMOYL ISONICOTINYL HYDRAZIDE; 4 AMINOCHALCONE; 4 IODO 2 HYDROXYCHALCONE; 4 METHOXY 2 HYDROXYCHALCONE; 4 METHOXY 4 NITROCHALCONE; ACETIC ACID DERIVATIVE; AMIDINOHYDRAZONE; ANTIMYCOBACTERIAL AGENT; CARBOXYOLEFIN; CHALCONE DERIVATIVE; CHEMOKINE RECEPTOR CCR2 ANTAGONIST; CINNAMIC ACID DERIVATIVE; ETHAMBUTOL; FUSIDIC ACID; HYDRAZIDE; ISONIAZID; LICOCHALCONE A; N [[2 (3,4 DIMETHOXYBENZYLIDENE)HYDRAZINYL](IMINO)METHYL] 3 (4 METHOXYPHENYL)ACRYLAMIDE; OFLOXACIN; PHENYL PHENYLACRYLAMIDE DERIVATIVE; RIFAMPICIN; RIFAMYCIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; BACTERIAL GROWTH; CELL MIGRATION; CHEMICAL STRUCTURE; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SOLUBILITY; DRUG SYNTHESIS; INFECTION SENSITIVITY; LIPOPHILICITY; MYCOBACTERIUM AVIUM; MYCOBACTERIUM BOVIS; MYCOBACTERIUM KANSASII; MYCOBACTERIUM MARINUM; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; REVIEW; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; CINNAMATES; DRUG DESIGN; HUMANS; LEGISLATION, DRUG; MOLECULAR STRUCTURE; PATENTS AS TOPIC; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84857520962     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2012.661717     Document Type: Review

References (39)

1. Warbasse JPL. Cinnamic acid in the treatment of tuberculosis. Ann Surg 1894;19:102-11
2. Jacobson MJ. Ethyl cinnamate in experimental tuberculosis. Bull Mem Soc med Hop Paris 1919;35:322-5
3. Corper HJ, Gauss H, Gekler WA. Studies on the inhibitory action of sodium cinnamate in tuberculosis. Colo Am Rev Tuberc 1920;4:464-73
4. Gainsborough H. A note on the use of benzyl cinnamic ester in tuberculosis. The method of Jacobsen. Lancet 1928;I:908-9
5. Chung HS, Shin JC. Characterization of antioxidant alkaloids and phenolic acids from anthocyanin-pigmented rice (Oryza sativa cv Heugjinjubyeo). Food Chem 2007;104(4):1670-7
6. Bezerra DP, Castro FO, Alves APNN, et al. In vivo growth-inhibition of Sarcoma 180 by piplartine and piperine, two alkaloid amides from Piper. Braz J Med Biol Res 2006;39:801-7
7. De P, Baltas M, Bedos-Belval F. Cinnamic acid derivatives as anticancer agents-A Review. Curr Med Chem 2011;18(11):1672-703
8. Naz S, Ahmed S, Rasool SA, et al. Antibacterial activity directed isolation of compounds from Onosma hispidum. Microb Res 2006;161(1):43-8
9. Carvalho SA, da Silva EF, de Souza MVN, et al. Synthesis and antimycobacterial evaluation of new trans-cinnamic acid hydrazide derivatives. Bioorg Med Chem Lett 2008;18(2):538-41
10. Nunn P, Williams MSB, Floyed K, et al. Tuberculosis control in the era of HIV. Nat Rev Immunol 2005;5(10):819-26
11. Rastogi N, Kochi A, Vareldzis SB, et al. Multidrug-resistant tuberculosis and its control. Res Microbiol 1993;144:103-58
12. Rastogi N, Ross BC, Dwyer B, et al. Emergence during unsuccessful chemotherapy of multiple drug resistance in a strain of Mycobacterium tuberculosis. Eur J Clin Microbiol Infect Dis 1993;11(10):901-7
13. Bloch AB, Cauthen GM, Onorato IM, et al. Nationwide survey of drug-resistant tuberculosis in the United States. J Am Med Assoc 1994;271(9):665-71
14. Reddy VM, Nadadhur G, Daneluzzi D, et al. Antimycobacterial activity of new rifamycin derivative, 3-(4- cinnamylpiperazinyl iminomethyl) rifamycin SV (T9). Antimicrob Agents Chemother 1995;39(10):2320-4
15. Dimova VA VI, Atanasova I, Tomioka H, et al. Experimental and clinical studies on rifacinna® - the new effective antituberculous drug. Recent Patents Anti Infect Drug Discov 2010;5(1):76-90
16. Konstantinova RG, Asenov VK, Dimova VI, et al. Disodium salt of 3-(4-cinnamyl-1-piperazinyl)iminomethyl rifamycin SV and process of preparation. US6476036; 2002
17. Chen Y-L, Huang S-H, Sun F-M, et al. Transformation of cinnamic acid from trans- to cis-form raises a notable bactericidal and synergistic activity against multiple-drug resistant Mycobacterium tuberculosis. Eur J Pharm Sci 2011;43(3):188-94
18. De P, Koumba Yoya G, Constant P, et al. Design, synthesis, and biological evaluation of new cinnamic derivatives as antituberculosis agents. J Med Chem 2011;54(5):1449-61
19. Peters W, Scott HM, Chambers HF, et al. Chemokine receptor 2 serves an early and essential role in resistance to Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2001;98(14):7958-63
20. Scott HM, Flynn JL. Mycobacterium tuberculosis in chemokine receptor 2-deficient mice: influence of dose on disease progression. Infect Immun 2002;70(11):5946-54
21. Buckland J. Chemokines: pulmonary paramedics. Nat Rev Mol Cell Biol 2001;2:564
22. Cai C, Sui Z. Piperidyl acrylamide antagonists of CCR2. WO2010008761; 2010
23. Kakawani MD, Suryavanshi P, Ray M, et al. Design, synthesis and antimycobacterial activity of cinnamide derivatives: a molecular hybridization approach. Bioorg Med Chem Lett 2011;21(7):1997-9
24. Koumba Yoya G, Bedos-Belval F, Constant P, et al. Synthesis and evaluation of a novel series of pseudo-cinnamic derivatives as antituberculosis agents. Bioorg Med Chem Lett 2009;19(2):341-3
25. Bairwa R, Kakwani M, Tawari NT, et al. Novel molecular hybrids of cinnamic acids and guanylhydrazones as potential antitubercular agents. Bioorg Med Chem Lett 2010;20(5):1623-5
26. Di Carlo G, Mascolo N, Izzo AA, et al. Flavonoids: old and new aspects of a class of natural therapeutic drugs. Life Sci 1999;65(4):337-53
27. Dimmock JR, Elias DW, Beazely MA, et al. Bioactivities of chalcones. Curr Med Chem 1999;6(12):1125-49
28. Ni L, Meng QC, Sikorski JA. Recent advances in therapeutic chalcones. Expert Opin Ther Patent 2004;14(12):1669-91
29. Dhar DN. The Chemistry of Chalcones and Related Compounds. John Wiley; New York: 1981
30. Nowakowska Z. A review of anti-infective and anti-inflammatory chalcones. Eur J Med Chem 2007;42(2):125-37
31. Go ML, Wu X, Liu XL. Chalcones: an update on cytotoxic and chemoprotective properties. Curr Med Chem 2005;12(4):483-99
32. Friis-Møller A, Chen M, Fursted K, et al. In vitro antimycobacterial andantilegionella activity of licochalcone a from Chinese licorice roots. Planta Med 2002;68(5):416-19
33. Kharzami A, Christensen SB, Ming C, et al. Treatment and prophylaxis of diseases caused by parasites or bacteria. WO9317671; 1993
34. Lin Y-M, Zhou Y, Flavin MT, et al. Chalcones and flavonoids as anti-tuberculosis agents. Bioorg Med Chem 2002;10(8):2795-802
35. Lin Y-M. Beta-fluoroethylthiourea compounds and use. US6677350; 2004
36. The global plan to stop TB 2011-2015. Transforming the fight towards elimination of tuberculosis. World Health Organization report. Available from: www.stoptb.org/assets/documents/global/ plan/TB-GlobalPlanToStopTB2011- 2015.pdf
37. Rastogi N, Goh KS, Van Ginkel SZ, et al. Identification of New drug targets in mycobacterium avium and mycobacterium tuberculosis. Res Microbiol 1996;147(1-2):97-105
38. Chew E-H, Nagle AA, Zhang Y, et al. Cinnamaldehydes inhibit thioredoxin reductase and induce Nrf2: potential candidates for cancer therapy and chemoprevention. Free Radic Biol Med 2010;48(1):98-111
39. Ma Q, Zhao X, Eddine AN, et al. The mycobacterium tuberculosis Lipb enzyme functions as a cysteine/lysine dyad acyltransferase. Proc Natl Acad Sci USA 2006;103(23):8662-7